Tag Archives | ipsen

Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for injection for the treatment of Lower Limb Spasticity in children aged two and older

The U.S. Food and Drug Administration (FDA) approved Ipsen Biopharmaceuticals’ supplemental Biologics License Application for Dysport (abobotulinumtoxinA) injection for the treatment of lower limb spasticity in pediatric patients ages 2 and older. “This approval means that, for the first time, physicians have an FDA-approved botulinum toxin with recommended dosing guidance for the treatment of children 2 years of […]

More ›